Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
NCT02521493Phase 3Active, not recruiting
- Sponsor
- Children's Oncology Group
- Start
- Dec 2015
- Primary completion
- Jun 2024
- Countries
- 6
01
Overview
A Phase 3 trial of cytarabine, daunorubicin, tioguanine, etoposide, mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Children's Oncology Group. Started Dec 2015; status: active, not recruiting.
02
Drugs
cytarabinedaunorubicintioguanineetoposidemitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02521493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02521493.